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Available online 20 February 2008For glioblastomas, COX-2 expression is linked to poor survival. COX-2 effects are mediated by the receptors
EP2 and EP4, whose regulation is poorly understood. The expression of EP4, and activation or inhibition of EP4
activity in human glioblastoma T98G cells, was found to correlate with growth on soft agar. Chemoprevention
drugs, troglitazone (TGZ) and some COX inhibitors, signiﬁcantly suppressed EP4 expression in T98G cells in a
dose dependant manner. Speciﬁcity protein 1 (Sp-1) binding sites, located within region −197 to −160 of the
human EP4 promoter, are important for the transcription initiation of the human EP4 gene and are responsible
for the EP4 suppression by TGZ. Mutation in the Sp-1 sites altered the promoter activity of luciferase
constructs and TGZ effects on the promoter. The inhibitory effect of TGZ on EP4 expression was reversed by
PD98059, a MEK-1/Erk inhibitor. Immunoprecipitation–Western blot analysis detected Sp-1 phosphorylation
that was dependent on TGZ-induced Erks activation. ChIP assay conﬁrmed that Sp-1 phosphorylation
decreases its binding to DNA and as a result, leads to the suppression of EP4 expression. Thus, we propose that
the expression of EP4 is regulated by Sp-1, but phosphorylation of Sp-1 induced by TGZ suppresses this
expression. This represents a new and unique mechanism for the regulation of the EP4 receptor expression.






Glioblastomas are the most common primary malignant tumors
arising from the CNS, and are one of the most lethal, treatment-
resistant human malignant tumors. Despite advancements in cancer
therapies including surgery, radiation therapy, and chemotherapy, the
median survival time is 12 to 15 months for patients newly diagnosed
with glioblastoma [1]. Thus, there is an urgent need for new
approaches for the treatment of glioblastomas. The overexpression
of cyclooxygenase-2 (COX-2) is observed in several human cancers
and increased COX-2 expression is associated with a poor prognosis in
colon [2], breast [3], ovarian [4], and pancreatic cancers [5]. COX-2
overexpression results in the overproduction of PGE2, promoting
tumor growth by binding to G protein-coupled receptors designated
EP1, EP2, EP3 and EP4. The EP receptor signaling pathways control cell
proliferation, invasion, apoptosis, and angiogenesis. EP2 and EP4
receptor activation is linked to increased β-catenin/T-cell factor
transcriptional activity via phosphorylation of glycogen synthase
kinase 3 (GSK-3) and hence it's inhibition [6]. Deletion of the EP2 and
EP4 receptors inmice causes a reduction of tumor growth in colorectal
[7] and breast [8] cancers. EP2 and/or EP4 expression is up-regulatednogenesis, National Institute of
alth, 111 TW Alexander Drive,
3911; fax: +1 919 541 0146.
.V.compared with normal tissues in colorectal [7] and breast [9] cancers.
EP4 mRNA expression is up-regulated in human astrocytoma cells
[10]. Raza et al. reported that the EP4 expression in 15 surgically
resected glioblastoma tissues is up-regulated compared to the ex-
pression in tissues from 5 anaplastic astrocytomas [11]. Shono et al.
reported that high COX-2 expression is associated with clinically more
aggressive gliomas and is a strong predictor of a poor survival [12].
Thus COX-2, via the activation of EP2 and EP4, is a potential modulator
of glioblastoma progression.
COX-2 inhibitors may be useful in preventing the development and
progression of glioblastomas, but the recently discovered toxic side
effects appears to eliminate their clinical usefulness. However, EP2 and
EP4 receptors are possible targets for new drug development and
antagonists, ordrugs that inhibit or suppressEP2/EP4expression, should
inﬂuence cancer development. The regulation of EP2 and EP4 has not
been extensively investigated. PPAR γ ligands inhibit the expression of
EP2 while PPAR β ligands increase the expression of EP4 in human lung
tumor cells [13,14]. In addition to inhibition of COX-1/-2, many COX
inhibitors alter gene expression [15,16], and these changes in expression
appear to contribute to the prevention of tumors by these drugs. Drugs
like sulindac sulﬁde and indomethacin, as well as other chemopreven-
tive drugs, increase the expression of the tumor suppression gene,
nonsteroidal anti-inﬂammatory drug-activated gene-1 (NAG-1) [17–19].
This increase in NAG-1 is mediated by altered expression of the
transcription factor early growth response gene 1 (Egr-1), whichmay be
a tumor suppressor altering the expression of a number of genes. The
Fig. 1. EP2 and EP4 expression in glioblastoma cells are increased relative to low grade
glioma cells. 2 lowgrade glioma cell lines (SW1783 and SW1088) and 5 glioblastoma cell
lines (A172, T98G, U87MG, U138MG and U373MG) were grown to 80–90% conﬂuency in
the appropriate media. Total protein (50 µg) was subjected toWestern blot analysis. The
anti-Actin antibody was used for a loading control. STD represents PPARγ standard that
was made by transfection of 5 μg PPARγ wild type expression plasmid into T98G cells.
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mechanism independent of PPARγ activation [20]. The mouse EP4
promoter contains many transcription sites including C/EBP, Sp1, and
AP-2, and these site are linked to responses to different stimuli [16]. Sp-1
sites frequently overlap with Egr-1 binding sites and interplay between
Egr-1 and Sp-1 exists, but a functional Egr-1/Sp-1 site has not been
characterized in the human EP4 promoter. In this report we have
investigated if drug induced changes in the expression of Egr-1/Sp-1
alters the expression of EP2 or EP4 in human glioblastomas.
2. Materials and methods
2.1. Cell lines and reagents
Human glioblastoma cell lines (A172, T98G, U87MG, U138MG, and U373MG) and
human astrocytoma cell lines (SW1783 and SW1088) were purchased from American
Type Culture Collection (Manassas, VA). Human glioblastoma cell lines were grown
in Eagle's minimal essential medium (EMEM) with 1 mM MEM Sodium Pyruvate
Solution (Gibco, Grand Island, NY), 2 mM L-Glutamine (Gibco), 10 μg/ml gentamicin
(Gibco), and 10% fetal bovine serum (FBS). Human astrocytoma cell lines were grown in
Leibovit's L-15 Media with 10 μg/ml gentamicin and 10% FBS. TGZ, Ciglitazone, Rosig-
litazone, MCC-555, Pioglitazone, the PPARα agonist Wy14643, EP4 agonist PGE1-OH,
and anti-EP2, anti-EP4, and anti-PPARγ antibodies were purchased from CaymanFig. 2. TGZ, sulindac sulﬁde, and indomethacin suppress EP4 expression dose-dependently
sulindac sulﬁde or 50 µM indomethacin for 48 h. EP2 and EP4 expression were measured by
additional 4 PPARγligands (30 µM CGZ, 10 µM RGZ, 10 µM MCC, and 10 µM PGZ)(B). T98G ce
graphs representmean±S.D. of EP2 or EP4/Actin of three experiments, each done in duplicate
MCC-555, PGZ: Pioglitazone.Chemical Co., Inc. (Ann Arbor, MI). The MEK-1/Erk Inhibitor PD98059 and the p38
inhibitor SB203580 were purchased from EMD Biosciences (San Diego, CA) and the PI3-
kinase Inhibitor Wortmannin, anti-phospho-Erk MAPK (Thr202/Tyr204), and anti-Egr-
1 antibodies were purchased from Cell Signaling Technology (Beverly, MA). Anti-Sp-1
(sc-59), anti-Sp-3 (sc-644), anti-Erk 1 (sc-93), anti-Erk 2 (sc-154), anti-phosphothreo-
nine (sc-5267), and anti-actin (sc-1615) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). EP 4 antagonist AH23848 was purchased from Sigma-
Aldrich (St. Louis, MO). All chemicals were dissolved in 0.1% Me2SO and stocked at
appropriate concentrations according to manufacturer's information.
2.2. Colony formation in soft agar assay
T98G cells were resuspended at 2×103 cells in 1 ml of 0.35% agar solution
containing MEM, 10% FBS, 1 mM MEM Sodium Pyruvate Solution, 2 mM L-Glutamine,
and the ﬁnal concentration of TGZ (20 μM), EP4 agonist (PGE1-OH) (10 μM) or EP4
antagonist (AH23848) (30 μM), then layered on top of a 0.7% agar layer in 6-well plates.
For EP4 knock-down or overexpression, T98G cells were transfected with 100 nM of
EP4 siRNA (M-005714-00, Dharmacon) or 3 µg of EP4 cDNA that was sub-cloned
into pcDNA3.1 from UMR cDNA Resource Center (Rolla, MO). The effect of EP4 knock-
down or overexpression was conﬁrmed by Western blot analysis and real-time RT-PCR
(data not shown). After 24 h transfection, the cells were trypsinized and resuspended
in 0.35% agar solution. Plates were incubated for 2 weeks at 37 °C in a 5% CO2 humidi-
ﬁed atmosphere. Cell colonies were visualized following an overnight stain with 0.5 ml
of p-iodonitrotetrazolium violet (Sigma-Aldrich) and examined microscopically. These
were represented asmean colony number examined in 10 randomly chosenmicroscope
ﬁelds.
2.3. Western blot analysis
Total cell lysates were isolated in RIPA buffer [1× PBS, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM Na3VO4, 1 mM NaF, 1 µM Okadaic acid, 10 mM
β-glycerolphosphate, and Complete Mini protease inhibitor cocktail tablets from
Roche (Indianapolis, IN). Quantitation of protein was performed by BCA assay (Pierce,
Rockfold, IL) and 50 μg of total proteins were separated by SDS-PAGE 4–12% Bis–Tris
gel (Invitrogen, Carlsbad, CA) and transferred onto a nitrocellulose membrane
(Invitrogen). The blots were blocked for 1 h with 5% skim milk in Tris-buffered saline
containing 0.05% Tween-20 (TBS-T) (Sigma-Aldrich) and probed overnight at 4 °C
with 5% skimmilk in TBS-T with each primary antibody. After washing with TBS-T, the
blots were incubated with the appropriate horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature with 5% skim milk in TBS-T and
washed several times in TBS-T. Proteins were detected by the enhanced chemillu-
minescence system (Amersham Biosciences, Piscataway, NJ).
2.4. Immunoprecipitation
1mg of nuclear extracts was preparedwith Nuclear Extract kit (ActiveMotif, Carlsbad,
CA) according to the manufacturer's protocol. The nuclear extract was precleaned with
60 µl of Protein A/G PLUS-Agarose (sc2003, Santa Cruz) by incubating for 1 h at 4 °C. After
pelleting agarose beads, the supernatant was transferred to a new tube and immunopre-
cipitated with 5 µg of anti-Sp-1 antibody overnight at 4 °C. For a negative control, normalin T98G cells. T98G cells were treated with Vehicle (0.1% Me2SO), 20 µM TGZ, 30 µM
Western blot analysis (A). For real-time RT-PCR analysis, T98G cells were treated with
lls were treated with these 3 drugs in different concentrations as indicated (C). The bar
. ⁎Pb0.01, signiﬁcant comparedwith Vehicle. CGZ: Ciglitazone, RGZ: Rosiglitazone, MCC:
Fig. 3. Alteration of EP4 expression affects soft agar growth. T98G cells were treated
with 10 µM PGE1-OH (EP4 agonist) or 30 µM AH23848 (EP4 antagonist) or co-treated
with 20 µM TGZ (A). ⁎Pb0.01, ⁎⁎Pb0.005, signiﬁcant compared with Control; †Pb0.005,
signiﬁcant compared with PGE1-OH; §Pb0.005, signiﬁcant compared with AH23848.
T98G cells were transiently transfected with EP4 cDNA or siRNA, then treated with
20 µM TGZ (B and C). The bar graphs represent mean±S.D of colony number of different
two experiments, each done in triplicate. ⁎Pb0.01, ⁎⁎⁎Pb0.001, signiﬁcant compared
with Control; †Pb0.005, signiﬁcant compared with pcDNA3.1 or Control siRNA;
‡Pb0.005, signiﬁcant compared with EP4 cDNA; ¶Pb0.01, signiﬁcant compared with
EP4 siRNA.
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Immunocomplex was collected by adding 40 µl of agarose beads and incubating for 3 h at
4 °C. After removal of the supernatant and washing the beads four times with RIPA buffer,
the beads were resuspended in 30 µl of 1× LDS buffer and boiled for 5 min at 100 °C. The
samples were separated by SDS-PAGE 4–12% Bis–Tris gel and transferred onto a
nitrocellulose membrane. The immunoprecipitated proteins were analyzed by immuno-
blotting using anti-phosphothreonine (p-Thr) antibody diluted 1:50.
2.5. Real-time RT-PCR
Real-time RT-PCR assays were performed using an ABI Prism 7700 (Applied
Biosystems, Foster City, CA). Real time RT-PCR ﬂuorescence detection was per-
formed in 96-well plates with Quantitect SYBR Green buffer (Qiagen). The sequences
of PCR primers (Invitrogen) used by real-time RT-PCR were designed according to
published data [10] and are as follows: Human EP2 5′-CGAGACGCGACAGTGGCTTCC-3′
(sense), 5′-CGAGACGCGGCGCTGGTAGA-3′ (antisense), Human EP4 5′-TCGCGCAAGGAG-
CAGAAGGACAC-3′ (sense), 5′-GACGGTGGCGAGAATGAGGAAGGA -3′ (antisense), Human
actin 5′-GCCGATCCACAGGGAGTA-3′ (sense), 5′-CCTGGCACCCAGCACAAT-3′ (antisense).
The experiments were performed in duplicate three times with individual time-matched
vehicle-treatedcontrols for eachgene tested. Ampliﬁedproduct sizewas routinelychecked
by gel electrophoresis on a 1% agarose gel in the presence of 0.1 µg/ml ethidium bromide
then visualized under UV light to conﬁrm that only one product was formed.
2.6. Constructions of plasmid
Human EP4 promoter luciferase constructs were generated by PCR using human
genomic DNA (Promega, MadisonWI). At ﬁrst, the EP4 promoter region of −1236 to −42
was generated using the primers 5′-GCAGATGGGAAGAGGTTTTT-3′ (sense) and 5′-TTC-
TCCTCCTCCAAGTTTCC-3′ (antisense). The primer designs were determined based on
the previously published sequence of the 5′-ﬂanking region upstream of the tran-
scription initiation site for human EP4 [21]. To construct the intact EP4 promoter region
(pEP4-1, −1238 to +1), which contains Nhe I (upstream) and Hind III (downstream)
restriction sites, PCR was subsequently carried out using the incomplete EP4 constructs
(−1236 to −42) as a template and the primers were designed as follows: 5′-GGGCT-
AGCCTGCAGATGGGAAGAGGTTTTTCCAGGAATTTAAA-3′ (sense), 5′-GGAAGCTTTG-
GAGCTCGCGTGCTGCGGCCTTTCCACCCTCTGTACAAACTTTTCTCCTCCT-3′ (antisense).
PCR products and the pGL3-basic vector (Promega) were digested with Nhe I and
Hind III restriction enzymes (New England Biolabs, Beverly, MA) and then puriﬁed with
QIAquick® PCR puriﬁcation kit (Qiagen). Puriﬁed products were ligated using DNA
Ligation kit Ver.2.1 (TaKaRa, Shiga, Japan) and sequenced-veriﬁed. Another EP4 pro-
moter deletion constructs were generated using the primers of following sequences:
pEP4-2 (−238 to +1): 5′-GGGGCTAGCCTCCGAGGGCGTGAAA-3′ (sense), pEP4-3 (−197
to +1): 5′-GGGGCTAGCGCCCAGCCCCGCCCCA-3′ (sense), pEP4-4 (−160 to +1): 5′-GG-
GGCTAGCAGTCTTCCCTGCGGC-3′ (sense). The sequence of antisense primer for all EP4
deletion constructs is as follows: 5′-GGAAGCTTTGGAGCTCGCGTGCTGCGGCCTTTC-3′.
The pEP4-3 constructs incorporated point mutations in Sp-1 or AP-2α binding sites
were created using QuikChange® II site-directed mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer′s protocol. Each Sp-1 or AP-2α binding site was
point-mutated to the two TT base pairs (indicated by underline) in pEP4-3 constructs and
primer designs were as follows: mut. Sp-1A pEP4-3: 5′-GCGCCCAGCCCTTCCCCAGCCCA-
GAC-3′, mut. Sp-1B pEP4-3: 5′-CAGCCCAGACACTTCCCCCCGCCAG-3′, mut. AP-2 pEP4-3:
5′-CAGCCCAGACACCGCCCCTTGCCAG-3′. Each construct was sequenced-veriﬁed to con-
ﬁrm the incorporation of the appropriate mutation. The PPARγ wild type plasmid was a
kind gift from Dr. Cary E. Clay (Department of Cancer Biology, Wake Forest University
Baptist Medical Center, Medical Center Boulevard, Winston Salem, North Carolina, 27157
USA). The Sp-1-dependent reporter plasmid containing 6 Sp-1 binding sites (pGAGC6) and
the control plasmid (pGAM)were kindly provided by Professor Jeffrey E. Kudlow (Division
of Endocrinology, Diabetes and Metabolism, The University of Alabama at Birmingham,
Birmingham, Alabama, 35294 USA). The Sp-1 expression plasmidwas reported previously
by our laboratory [22]. The mThr453/mThr739 Sp-1 expression plasmid, which has two
mutations of residues Thr453 and Thr739, was produced using QuikChange® XL site-
directed mutagenesis kit (Stratagene) and the sequences of PCR primers were described
previously [23].
2.7. Luciferase reporter assay
T98G cells were seeded in 6-well plates at 2×105 cells/well in EMEM and grown to
50–60% conﬂuence. The plasmid mixtures, containing 2 µg of EP4 promoter luciferase
construct and 0.05 µg of pRL-null (Promega), were transfected using FuGENE 6
Transfection Reagent (Roche) according to the manufacturer's protocol. The co-
transfection experiment was carried out using plasmid mixtures containing 1 µg of
pEP4-3 luciferase construct, 1 µg of expression plasmid (Sp-1 or mutant Sp-1), and
0.05 µg of pRL-null. The pcDNA3.1 empty vector (Invitrogen) was used as a negative
control for the expression plasmid. After 24 h transfection, the cells were treated with
indicated concentrations of PPARγ ligands (reported in the ﬁgure legends), 10 μM
Wy14643, or Control (0.1%Me2SO) for an additional 24 h. For PD98059 treatment study,
the cells were pretreated with 20 μM PD98059 for 1 h prior to the additional 24 h
treatment of 20 μM TGZ. Finally, the cells were harvested in 1× luciferase lysis buffer
(Promega) and luciferase activity wasmeasured and normalized with the values of pRL-
null luciferase activity using a dual luciferase assay kit (Promega).2.8. Short interfering RNA (siRNA) transfection
The Sp-1 siRNA (M-026959-00), Sp-3 siRNA (M-023096-01), and control siRNA
(D-001206-08-05) were purchased from Dharmacon (Lafayette, CO). T98G cells were
grown to 70–80% conﬂuence in antibiotic-free EMEM medium and transfected with
each siRNA at 100 nM using Lipofectamine™ 2000 reagent (Invitrogen) and Opti-
MEM® medium (Gibco) according to the manufacturer's instructions. After incu-
bating for 5 h, the cells were washed and changed to the complete media and re-
covered overnight. After conﬁrming the knock-down of target genes by Western blot
analysis, the cells were subsequently treated for 48 h and the effect of EP4 expression
by Sp-1 or Sp-3 knock-down was investigated with Western blot analysis.
2.9. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the ChIP assay kit (Upstate Biotechnology, Lake
Placid, NY) according to the manufacturer's protocol. Brieﬂy, T98G cells (3×107) were
treated with the indicated conditions for 24 h and then ﬁxed with 1% formaldehyde for
10 min at 37 °C. The ﬁxed cells were scraped into conical tubes, pelleted, and lysed in
SDS lysis buffer containing 1 mM phenylmethylsulfonyl ﬂuoride, 1 µg/ml aprotinin, and
1 µg/ml pepstatin A. DNA was sheared to fragments of 200–800 bp by sonication
10 times for 20 s at a 50% constant maximum power. The sonicated cell supernatant was
diluted 10 fold in the ChIP dilution buffer and 1% of the diluted cell supernatant was
kept as a positive control (Input). The chromatin was precleared with salmon sperm
DNA/protein A-agarose slurry for 1 h at 4 °C. The precleared supernatant was incubated
with antibodies against Sp-1 (sc-59X, Santa Cruz), Sp-3 (sc-644X), or normal rabbit IgG
overnight at 4 °C. The immunocomplexes were elutedwith elution buffer (1% SDS, 0.1 M
NaHCO3, 10 mM DTT). 5 M NaCl was added into eluted samples to reverse histone-DNA
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used as a template for PCR ampliﬁcation. The region between −238 and −103 of the
human EP4 promoter was ampliﬁed using the following primers: 5′-CTCCGAGGGCGT-
GAAAAC-3′ (sense), 5′-CATTGGCCGGATTGGAAG-3′ (antisense). The 136 bp products
were resolved on a 2% agarose gel and visualized under UV light.
2.10. Statistical analysis
All statistical differences between experimental groups were evaluated by the two-
tailed unpaired Student's t test.
3. Results
In order to select a suitable cell line for this investigation, we ﬁrst
examined the expression levels of EP2 and EP4 in 5 glioblastoma cell
lines (A172, T98G, U87MG, U138MG, and U373MG) and 2 lower grade
glioma cell lines (SW1783 and SW1088) with Western blotting
analysis. EP2 and EP4 expression were observed in all cells, but the
expressions in the glioblastoma cells were higher relative to the lower
grade glioma cells (Fig. 1A). This ﬁnding suggests that EP2 and EP4
expression might correlate with tumor malignancy in human glioma
cells. The expression of PPARγ-1/2 was also examined by Western
blotting analysis and was undetectable in all glioblastoma cell lines
(Fig. 1B). These cells express COX-1 and COX-2 after treatment with
cytokines [24] and T98G cells were selected for further experiments
because of the high expression of EP2 and EP4 proteins.
3.1. Suppression of the EP2/EP4 expression
In order to determine if anti-cancer drugs that increase or alter Egr-
1/Sp-1 expressionwould likewise alter the expression of either EP2 or
EP4, T98G cells were treated with sulindac sulﬁde (30 μM), indo-
methacin (50 μM), TGZ (20 µM), and vehicle (0.1% Me2SO) for 48 h. As
shown in Fig. 2A, sulindac sulﬁde, indomethacin, and TGZ signiﬁcantly
suppressed the expression of EP4, and had only a modest inhibitory
effect on EP2 expression. Other PPARγ ligands Rosiglitazone, MCC-
555, Pioglitazone, (10 µM each), and Ciglitazone (30 µM) had no effectFig. 4.MEK-1/Erk pathway is involved in EP4 suppression by TGZ treatment. T98G cells wer
(p38 MAPK inhibitor) or 100 nMWortmannin (PI3-K inhibitor) prior to the addition of TGZ (
time RT-PCR (B). The bar graphs represent mean±S.D. of EP4/Actin of three experiments, eaon either EP2 or EP4 expression as determined with real time RT-PCR
analysis (Fig. 2B). Thus the suppression of EP4 by TGZ is independent
of PPARγ and is in agreement with the absence of PPARγ expression in
these cells. The inhibition of EP4 expression by these drugs was
concentration-dependent (Fig. 2C). Prostaglandins activate EP4 recep-
tors and activation of EP4 will increase Egr-1 expression [25]. Thus,
inhibition of prostaglandin formation by sulindac sulﬁde and
indomethacin could add further complexity to the study with T98G
cells because they express COX-1/2 [26]. Thus, we decided to focus on
TGZ as it does not alter prostaglandin formation, as a tool to
investigate Egr-1/Sp1 and EP4 suppression.
3.2. EP4 expression and soft agar growth
The growth of cells in soft agar is an estimate of tumorigencity and
is frequently used to examine the effects of drugs and changes in gene
expression on tumorigencity. Cells were treated with TGZ, PGE1-OH
(EP4 agonist), or AH23848 (EP4 antagonist), and the number of
colonies was measured after 2 weeks. Incubation of the cells with TGZ
inhibited colony growth by ~50%. The EP4 agonist increased the
colony number; however, the increase was blocked by co-treatment of
TGZ. AH23848 (EP4 antagonist) inhibited the soft agar growth of T98G
cells and was further inhibited by co-treatment of TGZ (Fig. 3A). We
next transiently transfected EP4 cDNA or siRNA into T98G cells, then
treated the cells with and without TGZ. As shown in Fig. 3B, the EP4
overexpression increased colony number, but co-incubation with TGZ
reduced the increase. In contrast, EP4 siRNA inhibited the expression
of EP4 and decreased cell growth (Fig. 3C). These ﬁndings are in
agreement with the results from treatment with the EP4 agonist or
antagonist. Thus an increase in EP4 expression or activation of the
receptor increases colony growth, while the decrease in EP4 expres-
sion or inhibition of receptor activity reduces colony number. The data
suggest that EP4 expression is an important component in the TGZ
inhibition of colony growth on soft agar and indicates the importance
of EP4 in tumorigenesis.e pretreated with or without 20 µM PD 98059 (MEK-1/Erk inhibitor), 10 µM SB 203580
20 µM) for 48 h. EP4 expression was measured with Western blot analysis (A) and real-
ch in duplicate. ⁎Pb0.01, signiﬁcant compared with TGZ.
Fig. 6. TGZ suppresses human EP4 promoter activity. Each human EP4 promoter
construct (pEP4-1), other deletion constructs (pEP4-2 to 4) or pGL3-basic vector was
transfected into T98G cells for 24 h. The cells were treated with Control (0.1% Me2SO) or
TGZ (20 µM) for 24 h (A). The pEP4-3 or pGL3 was transfected into T98G cells for 24 h.
The transfected cells were treated with 5 PPARγ ligands (20 µM TGZ, 30 µM CGZ, 10 µM
RGZ, 10 µM MCC, or 10 µM PGZ) or one PPARα ligand (10 µM Wy14643) for 24 h (B).
Luciferase activity was measured by a dual luciferase assay system. The bar graphs
represent mean±S.D. of RLU of three experiments. ⁎Pb0.01, signiﬁcant compared with
RLU of Control.
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Various MAPK pathways mediate TGZ effects in several tumor cell
lines [27,28]. This laboratory previously reported data conﬁrming the
requirement for Erk in TGZ mediated increase of NAG-1 by the Egr-1
transcription pathway [20]. To determine which MAPK pathways are
involved in the suppression of EP4 expression by TGZ, T98G cells were
pretreated for 1 h with or without MEK-1/Erk inhibitor PD98059
(20 µM), p38 MAPK inhibitor SB203580 (10 µM), and PI3-kinase
inhibitor Wortmannin (100 nM), and subsequently co-treated with
TGZ or vehicle as indicated. Only the MEK-1/Erk inhibitor reversed the
TGZ-induced EP4 suppression (Fig. 4A). This ﬁnding was consistent
with real-time RT-PCR analysis of mRNA levels (Fig. 4B). Thus, the
MEK-1/Erk pathway is involved in the suppression of EP4 expression
by TGZ.
3.4. Time dependent expression of Egr-1/Sp-1 and EP4
In previous experiments, we observed a rapid increase followed by a
decrease in Egr-1 expression in response to TGZ treatment of HCT-116
human colorectal cells [29]. Sp-1 expressionwas not measured in these
experiments. The time course for the expression of Egr-1, Sp-1, and EP4
in response to TGZ treatment was examined in more detail in the
glioblastomacells. A rapid increase inEgr-1 expression, peakingat3–4h,
followed by a rapid decline was observed after treatment with TGZ in
T98G cells. The expression of Sp-1 also increased, but was slower than
Egr-1, peaked at 16 h, and then slowly declined over 48 h of treatment.
For EP4, a slight increase in expression (1.5-fold) was observed at 8 to
16handwas followedbyadeclineof expression to approximately 50%of
the zero time control at 48 h. Total Sp-1 expression increased about 2.5-
fold after 16 h of TGZ treatment (Fig. 5). These data point to Sp1, and not
Egr-1, as an important transcription factor regulating EP4.
3.5. TGZ suppresses EP4 promoter activity
To examine the cis-acting elements in the EP4 promoter, which are
responsible for EP4 suppression, T98G cells were transfected with a
1.2 kb EP4 promoter (pEP4-1), deletion constructs (pEP4-2 to 4), or
pGL3-basic empty vector and then treatedwith TGZ for 24 h. As shown
in Fig. 6A, TGZ suppressed the EP4 luciferase activities of pEP4-1 to -3
constructs transfected cells. Deletion of an additional 37 nucleotides
from −197 to −160 (pEP4-4) abolished TGZ-induced suppression.
Furthermore, 4 additional PPARγ ligands (Ciglitazone, Rosiglita-
zone, MCC-555, and Pioglitazone) and one PPARα ligand (Wy14643)
did not suppress luciferase activity (Fig. 6B), suggesting that the
suppression is unique toTGZ. These data suggest that the TGZ response
element is located in the region between −197 and −160 of the EP4
promoter.Fig. 5. Time course for expression of Sp-1, Egr-1 and EP4 in T98G cells. T98G cells were
treated with 20 µM TGZ at different time points as indicated. The expression change of
Sp-1, Egr-1 and EP4 was measured withWestern blot analysis. The bar graphs represent
the fold change of mean±S.D. of Egr-1, Sp-1 or EP4/Actin compared to 0 h of three
experiments, each done in duplicate. ⁎Pb0.01, †Pb0.005, signiﬁcant compared to 0 h.3.6. Sp-1 binding site is responsible for EP4 suppression
There are two Sp-1 binding sites (Sp-1 A and Sp-1 B) and an AP-2α
binding site overlapping with Sp-1B site [21] (Fig. 7A) in the region
between −197 and −160 of the human EP4 promoter. To determine if
the Sp-1 or AP-2α binding sites are responsible for the EP4
suppression by TGZ, we generated point mutations in the Sp-1 and
AP-2α binding sites of pEP4-3 constructs (Fig. 7A). The point
mutations in the AP-2α binding site did not alter the suppression of
EP4 luciferase activity by TGZ. In contrast, the luciferase activity of the
mutant Sp-1A, B constructs was not suppressed by TGZ relative to the
wild-type construct, indicating that these two Sp-1 binding sites are
responsible for the transcription initiation of the EP4 gene (Fig. 7B). To
conﬁrm the binding of Sp-1 to DNA at the responsible Sp-1 binding
sites, we performed a ChIP assay with primers that amplify the
identiﬁed TGZ response element containing the two Sp-1 binding sites
in the human EP4 promoter. As shown in Fig. 7C, Sp-1 bound to
the DNA and treatment with TGZ markedly decreased DNA binding of
Sp-1 relative to the control. Incubation with RGZ that does not inhibit
EP4 expression also did not alter the binding of Sp-1 to DNA. The
inhibitory effect of TGZ on Sp-1 binding was reversed by pretreatment
with PD98059 as an Erk kinase inhibitor. This ﬁnding further supports
the involvement of MEK-1/Erk pathway in the inhibition of EP4
expression by TGZ. The ChIP assay with anti-IgG failed to produce PCR
products. Sp-3, a member of the Sp families, is reported to inhibit Sp-1
mediated transcription, but immunoprecipitation with an antibody
for Sp-3 and the use of speciﬁc primers for Sp-3 failed to produce PCR
Fig. 7. Sp-1 binding site is responsible for EP4 suppression in T98G cells. Two Sp-1 binding sites (Sp-1A and Sp-1B) are located in the region between −197 and −160 of the human EP4
promoter. The AP-2α binding site overlaps with the Sp-1B site. Each Sp-1 or AP-2α binding site was point-mutated to TT base pairs in pEP4-3 constructs (A). The wild pEP4-3, each
mutant pEP4-3, or pGL3 was transfected into T98G cells for 24 h. After 24 h treatment, luciferase activity was measured (B). The bar graphs represent mean±S.D. of RLU of three
experiments. ⁎Pb0.01, signiﬁcant compared with each RLU of Control. T98G cells were plated in 10-cm plates at 3×107 cells/plate and grown to 60–70% conﬂuency. The cells were
pretreatedwith or without PD98059 before addition of TGZ (20 µM), RGZ (10 µM) or Control, then ﬁxedwith 1% formaldehyde. 3 µl of each puriﬁed samplewas used as a template for
PCR ampliﬁcation (C and D). 1 µg of pGAGC6 plasmid, which contains 6 Sp-1 binding sites or pGAM control plasmid and 0.05 µg of pRL-null were co-transfected into T98G cells and
the cells were incubated for 24 h, followed by treatment with TGZ, RGZ or Control for 24 h (E). The bar graphs represent mean±S.D. of RLU of three experiments. ⁎Pb0.01, signiﬁcant
differences as compared with RLU of Control.
Fig. 8. Sp-1 is essential for the expression of EP4 in T98G cells. The pEP4-3 or pGL3 and
Sp-1 expression plasmids or pcDNA3.1 were co-transfected into T98G cells for 24 h.
After 24 h treatment with TGZ or Control, luciferase activity was measured (A).
⁎; Pb0.01, signiﬁcant compared with pcDNA3.1+Control; †; Pb0.005, signiﬁcant
compared with Sp-1+TGZ. Sp-1 or Control siRNA was transfected into T98G cells and
the knock-down of Sp-1 was conﬁrmed by Western blot analysis (B). After transfection
of Sp-1 or Control siRNA, EP4 protein was measured with Western blot analysis (C).
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reporter plasmid (pGAGC6) containing 6 Sp-1 binding sites was
transfected into T98G cells and the cells were treated with TGZ or RGZ
(a PPARγ ligand). Only the TGZ treatment markedly suppressed the
luciferase activity of pGAGC6 transfected cells (Fig. 7E). Taken
together, these data indicate that the Sp-1 binding sites in the
promoter play a critical role in EP4 suppression.
3.7. Sp-1 is essential for the expression of EP4 in T98G cells
As shown in Fig. 8A, the co-transfection of pEP4-3 and Sp-1
expression plasmid increased EP4 luciferase activity, but the co-
transfection of pEP4-3 and Sp-1 followed by TGZ treatment markedly
suppressed the activity relative to the cells transfected with the
pcDNA3.1 vector. Sp-1 siRNA transfected into T98G cells and inhibition
of Sp-1 expression was ﬁrst conﬁrmed by Western blot analysis
(Fig. 8B). As shown in Fig. 8C, the transfection of Sp-1 siRNA
dramatically suppressed EP4 expression relative to the transfection
of control siRNA. To determine if the response was speciﬁc for Sp-1,
cellswere transfectedwith Sp-3 siRNA. Sp-3 siRNA transfection did not
affect EP4 suppression (data not shown). These ﬁndings indicate that
the transcription factor, Sp-1 is essential for the expression of EP4 in
T98G cells.
3.8. Sp-1 phosphorylation and the inhibitory effect of TGZ
As shown in Fig. 4, MEK-1/Erk inhibitor PD98059 prevented the
EP4 suppression by TGZ. We ﬁrst conﬁrmed the phosphorylation of
Erk 1/2 proteins by TGZ treatment of T98G cells. TGZ dramatically
induced Erk1/2 phosphorylation observed as early as 15 min after
treatment which then declined (Fig. 9A). These ﬁndings suggest that
the activated Erks may alter Sp-1 expression and alter its phosphor-
ylation Phosphorylated Erks and total Sp-1 proteins were measured
after 1 h pretreatment of different concentrations of PD98059
followed by treatment with TGZ. The phosphorylation of Erk 1/2
and Sp-1 protein expression induced by TGZ were blocked byPD98059 in a concentration dependent manner (Fig. 9B). Erks can
phosphorylate two speciﬁc threonine-residues (Thr453, Thr739) and
other sites in Sp-1 [30]. After TGZ treatment of the cells, phosphory-
lated threonine-residues in Sp-1 were analyzed by immunoprecipita-
tion with antibodies for Sp-1 followed by Western blot analysis with
p-Thr and Sp-1. Phosphorylated Sp-1 was detected and pretreatment
with PD98059 inhibited the formation of phosphorylated Sp-1
(Fig. 9C). Thus TGZ induced the phosphorylation of Sp-1 dependent
on Erks activation and appears to play a key role in the inhibition of
Fig. 9. Sp-1 is induced by TGZ via MEK-1/Erk pathway. T98G cells were treated with TGZ at indicated time points. Total or phospho-Erk1/2 expressionwas measured byWestern blot
analysis (A). T98G cells were pretreated with different amounts of PD98059 for 1 h prior to the addition of TGZ for 15 min (p-Erks) or 16 h (Sp-1). Sp-1 or phospho-Erk1/2 expression
wasmeasured byWestern blot analysis (B). T98G cells were pretreatedwith or without 20 µM PD98059 for 1 h, then co-treatedwith TGZ or Control for 16 h. The immunoprecipitated
proteins were subjected to Western blot analysis with anti-phosphothreonine or anti-Sp-1 antibody (C). The pEP4-3 or pGL3 and Sp-1 plasmid were co-transfected into T98G cells.
After 24 h incubation, the cells were pretreated with or without PD98059 at different concentrations for 1 h, and then co-treated with TGZ for 24 h (D). ⁎Pb0.01, signiﬁcant compared
with Control; †Pb0.01, signiﬁcant compared with TGZ treatment. The bar graphs represent mean±S.D. of RLU of three experiments. The pEP4-3 or pGL3 and pcDNA3.1, wild Sp-1 or
mThr453/mThr739 Sp-1 expression plasmid were co-transfected into T98G cells for 24 h, then treated with TGZ for 24 h (E). The bar graphs represent mean±S.D. of RLU of three
experiments. ⁎Pb0.001, signiﬁcant compared with pcDNA3.1; †Pb0.01, signiﬁcant compared with Sp-1.
Fig. 10. TGZ induces EP4 suppression via Sp-1 phosphorylation. TGZ activates MEK-1/
Erk pathway and induces phosphorylation of Erks, which causes the threonine
phosphorylation of Sp-1. Sp-1 phosphorylation decreases the DNA binding of Sp-1
binding sites located in the region between −197 and −160 of the human EP4 promoter,
leading to the suppression of EP4 expression.
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PD98059 reversed the inhibition of the EP4 reporter activity by TGZ
(Fig. 9D). To further conﬁrm the importance of Sp1 phosphorylation,
we co-transfected pEP4-3, the mThr453/mThr739 Sp-1 expression
plasmid, which has two mutations of residues Thr453 and Thr739, or
wild Sp-1 expression plasmid into T98G cells, and subsequently
treated the cells with TGZ. EP4 promoter activity was suppressed by
Sp-1 overexpression, while the transient transfection of mutated Sp-1
expression plasmid was not as effective (Fig. 9E). The Sp-1 protein and
mutant Sp-1 expression protein were equally expressed (data not
shown). Thus threonine phosphorylation of Sp-1 is involved in the EP4
suppression by TGZ, but other sites of phosphorylation may also be
involved. These ﬁndings point to a critical role for the phosphorylation
of Sp-1 in the suppression of EP4 expression by TGZ.
4. Discussion
PGE2, by binding its receptors, plays a predominant role in
promoting tumor progression. Several reports, including knock-out
studies, reveal EP4 to be important in tumor progression mediated by
PGE2 [31,32]. In glioblastomas, high COX-2 expression is associated
with more aggressive gliomas and is a strong predictor of poor
survival [12]. With the glioblastomas cells examined in this study, the
expression of EP4 appears to correlate with the grade of the tumor
(Fig. 1A). The growth of T98G cells on soft agar, a measure of
tumorigenicity, is either increased or decreased by a corresponding
change in the expression levels of EP4 in these cells. Drugs like TGZ
appear to suppress growth on soft agar, in part, by reducing EP4
expression. How EP4 activation increases tumor growth is not clear,
but EP4 inhibits glycogen synthase kinase-3 (GSK-3) via the PI3/Akt
pathway, hence increasing the transcriptional activity of β-catenin [6].
PGE2 stimulates colon cancer growth via β-catenin [33]. EP4 activation
also induces Erk signaling via PI3-kinase [25], which is involved in
tumor cell proliferation by PGE2 [34]. Thus, the suppression of EP4
expression reduces critical oncogenic pathways and suppresses tumor
growth.
In this report, we present evidence supporting the hypothesis that
TGZ suppresses EP4 expression by increasing the phosphorylation of
the transcription factor Sp-1 (Fig. 10). Chien et al. reported that a GC
rich/Sp-1 binding site is important in transcription initiation of the rat
EP4 gene [35]. The human EP4 promoter region contains 2 Sp-1 sites
and mutation of these sites in luciferase promoter studies conﬁrmedthat Sp-1 sites are important in regulation of EP4 expression. In
addition, the ChIP assay conﬁrmed that the Sp-1 sites are important
for TGZ suppression of EP4 expression. Sp-1 siRNA decreases the
expression of Sp-1 and results in a decrease in the expression levels of
EP4. Sugawara et al. showed that TGZ suppresses TP gene transcrip-
tion via an interaction of Sp-1/DNA complex in rat vascular smooth
muscle cells, which express PPARγ [36]. They proposed that the
activation of PPARγ decreased the binding of Sp-1 to DNA, and led to a
decrease in the expression of TP. However, we could not detect the
expression of PPARγ by Western blot analysis in T98G cells. In
addition, there is no obvious PPRE in human EP4 promoter region [21]
supporting the conclusion that TGZ-induced EP4 suppression is not
dependent on the PPARγ pathway. Thus EP4 suppression by TGZ is
independent of PPARγ and the mechanisms are different from the
observations of Sugawara.
We also investigated the involvement of Sp-3 in EP4 suppression
by TGZ, because Sp-3 is known to bind to GC rich sites and inhibit Sp-1
induced transcription. Sp-3 protein expression was not changed by
TGZ treatment (data not shown). Additionally, the ChIP assay revealed
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transfection of Sp-3 siRNA had no affect on EP4 suppression (data not
shown). These data indicate that Sp-3 is not involved in TGZ-induced
EP4 suppression.
Erks activation plays a role in the suppression of EP4 and the Erk
kinase inhibitor prevents TGZ-induced suppression of EP4 expression.
Sp-1 protein is phosphorylated by several kinases including Erk. Five
phosphorylation sites (Ser59, Ser131, Thr453, Thr579 and Thr739) have
been identiﬁed in Sp-1 [23,30,37] and threonine phosphorylation at
Thr453 and Thr739 occurs in response to Erks activation [30].
Phosphorylation of Sp-1 decreases DNA binding activity and transcrip-
tion activation of target genes. In this study, we detected phosphory-
lated threonine residues in Sp-1 activated by TGZ-induced Erks
(Fig. 9C). In addition, EP4 suppression by TGZ was partially restored
by the transient transfection of mThr453/mThr739 Sp-1 expression
plasmid (Fig. 9E). The ChIP assay experiment revealed that TGZ
decreases DNA binding activity of responsible Sp-1 binding sites in
human EP4 promoter (Fig. 7C). Fischer et al. reported that inhibition of
the Ras–MEK–Erk cascade bygalectin-1 increased Sp-1 transactivation
and DNA binding due to reduced threonine phosphorylation of Sp-1
[38]. Taken together, these data suggest that phosphorylation of Sp-1 is
critical and results in the decrease in Sp-1 DNA binding, and hence
suppression of transcription activation of target genes like EP4 is
observed.
Sp-1 is a member of a family of zinc ﬁnger transcription factors and
binds to the GC-rich sequences and can overlap with Egr-1 sites. Sp-1
plays important roles in a wide range of cellular processes including
cell cycle regulation, hormonal activation, apoptosis, and angiogenesis
[39]. Egr-1, a transcription factor, is also involved in cell growth and
differentiation. Egr-1 has been proposed as a tumor suppressor and
regulates the expression of the NAG-1/MIC/GDF15 protein, which is
reported to suppress intestinal tumor formation [40]. In our previous
publication, we observed that TGZ induced Egr-1 via Erks activation
[20].We conﬁrmed the induction of Egr-1 by TGZ inT98G cells, but Egr-
1 overexpression did not cause a further reduction of pEP4-3 luciferase
activities (data not shown), even thoughEgr-1might overlapwith Sp-1
binding sites. Drugs like TGZ appear to increase the expression of Sp-1
and Egr-1 and alter the phosphorylation of these proteins via Erk
kinases [19,41]. As a consequence of these actions, NAG-1 is initially
induced and is followed by a suppression of EP4 expression. Both of
these events act tomodulate tumor progression. Thus the inhibition of
tumor growth by TGZ is very complex and involves a number of signal
transduction pathways. Stimulation of Sp-1 phoshorylation and the
subsequent suppression of EP4 expression is a novel mechanism to
explain the anti-tumorigenic property of TGZ and may provide a new
rationale for the development of drugs for the prevention or treatment
of cancer. Because the side effects of speciﬁc COX-2 inhibitors appear to
preclude their use as cancer prevention drugs, a new approach is to
target down stream of COX-2. Suppression of EP4 expression is a likely
candidate based on our ﬁndings.
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